GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival (PFS) readout ahead of its potential U.S. return in multiple myeloma this ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease. Blenrep (belantamab mafodotin) has been ...

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a combination treatment for multiple myeloma (MM). The health ...

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.

FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.

GSK (NYSE: GSK) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its antibody-drug conjugate Blenrep as a late-line option and as part ...

The National Institute for Health and Care Excellence (Nice) has approved Blenrep, manufactured by GlaxoSmithKline, for use within the NHS.